T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies ...

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Immatics (NASDAQ:IMTX – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $4.83 and last traded at $4.85, with a volume of 566228 shares trading ...